|
Leap Therapeutics ، Inc. (LPTX) DCF تقييم |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Leap Therapeutics, Inc. (LPTX) Bundle
تبحث لتقييم القيمة الجوهرية لـ Leap Therapeutics ، Inc.؟ تدمج حاسبة DCF (LPTX) DCF بيانات العالم الحقيقي مع ميزات تخصيص شاملة ، مما يتيح لك تحسين توقعاتك واتخاذ خيارات استثمار أكثر استنارة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | -100 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -26.8 | -40.0 | -54.0 | -81.0 | -70.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -1787.27 | -2667.6 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .7 | .6 | .4 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 44.53 | 37.07 | 100 | 100 | 100 | 76.32 | 76.32 | 76.32 | 76.32 | 76.32 |
| EBIT | -27.5 | -40.6 | -54.4 | -81.4 | -70.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -1831.8 | -2704.67 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 52.1 | 114.9 | 65.5 | 70.6 | 47.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | 1.2 | 2.1 | .8 | .7 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 4.87 | 79.27 | 100 | 100 | 100 | 76.83 | 76.83 | 76.83 | 76.83 | 76.83 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 2.7 | 4.2 | 5.7 | 6.5 | 4.7 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 181.13 | 279.27 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 | -1.22 |
| EBITAT | -27.5 | -40.5 | -54.5 | -81.4 | -70.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -24.2 | -39.6 | -53.6 | -78.9 | -72.6 | -4.0 | .0 | .0 | .0 | .0 |
| WACC, % | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 | 5.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -47 | |||||||||
| Equity Value | 43 | |||||||||
| Diluted Shares Outstanding, MM | 38 | |||||||||
| Equity Value Per Share | 1.15 |
What You Will Receive
- Comprehensive Financial Model: Leap Therapeutics’ actual data supports accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to see outcomes as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, enabling repeated use for in-depth forecasts.
Key Features
- Customizable Clinical Parameters: Adjust vital inputs such as patient demographics, treatment efficacy, and trial durations.
- Automated Valuation Models: Instantly computes intrinsic value, NPV, and other key metrics.
- High-Precision Analytics: Leverages Leap Therapeutics' actual financial data for credible valuation results.
- Streamlined Scenario Testing: Easily evaluate various assumptions and analyze outcomes side by side.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file for Leap Therapeutics, Inc. (LPTX).
- Step 2: Review the pre-filled financial data and forecasts specific to Leap Therapeutics.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose Leap Therapeutics Calculator?
- Accuracy: Utilizes real Leap Therapeutics financials to ensure precise data.
- Flexibility: Crafted for users to easily test and adjust inputs as needed.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Designed with CFO-level precision and user experience in mind.
- User-Friendly: Simple to navigate, even for those without extensive financial modeling background.
Who Should Use This Product?
- Investors: Assess Leap Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Leap Therapeutics.
- Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
- Students and Educators: Utilize real-time data to learn and teach valuation principles in biotechnology.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Leap Therapeutics, Inc. (LPTX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Leap Therapeutics, Inc. (LPTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.